A Phase 3 interventional study of Elagolix and Placebo for Estradiol/Norethindrone Acetate in Uterine Fibroids and Heavy Menstrual Bleeding, sponsored by AbbVie. Completed at 96 sites in 3 countries. Open to female participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2020-06-29.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Leiomyoma by AbbVie — none open to participants now, none under way, none of them phase 3. Leiomyoma · AbbVie.
Among the 33 studies in Leiomyoma by AbbVie, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2015, is one of 14 in phase 3, and was the 24th registered.
438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →None of the 33 studies in Leiomyoma by AbbVie is open now. The open studies under Leiomyoma, anywhere →
Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 51 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 14 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 66 across 306 interventional studies indexed under Leiomyoma.
Median enrollment 61 across the 28 interventional studies, 0 across the 5 observational. Of the 28 that completed or were terminated, 22 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Leiomyoma by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
Drug: Placebo for Estradiol/Norethindrone Acetate · Drug: Placebo for Elagolix
Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
Drug: Elagolix · Drug: Placebo for Estradiol/Norethindrone Acetate
Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
Drug: Elagolix · Drug: Estradiol/Norethindrone Acetate
Film-coated tablets
Also known as: ABT-620, elagolix sodium
Placebo capsules
Drug pages: Estradiol · Norethindrone Acetate
Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Also known as: E2/NETA
Film-coated placebo tablets
Percentage of Participants Meeting the Criteria for Responder
Percentage of responders, defined as participants who met the following conditions: * Menstrual blood loss (MBL) volume \< 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period \[last treatment visit date\] or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and * ≥ 50% reduction in MBL volume from Baseline to the Final Month. Participants who prematurely discontinued study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or "adverse events" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.
Time frame: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Change From Baseline in MBL Volume to the Final Month
Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.
Time frame: Month 0 (Baseline), Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Percentage of Participants With Suppression of Bleeding at the Final Month
Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.
Time frame: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Change From Baseline in MBL Volume to Month 6
Time frame: Month 0 (Baseline), Month 6
Change From Baseline in MBL Volume to Month 3
Time frame: Month 0 (Baseline), Month 3
Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
Time frame: Month 0 (Baseline), Month 6
Change From Baseline in MBL Volume to Month 1
Time frame: Month 0 (Baseline), Month 1
| Milestone | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Started | 102 | 104 | 207 |
| Randomized and treated | 102 | 104 | 206 |
| Completed | 83 | 81 | 164 |
| Not completed | 19 | 23 | 43 |
| Milestone | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Started | 25 | 32 | 59 |
| Completed | 17 | 24 | 29 |
| Not completed | 8 | 8 | 30 |
| Withdrew: Withdrawal by subject | 2 | 6 | 7 |
| Withdrew: Lost to follow-up | 3 | 0 | 13 |
| Withdrew: Required surgery/invasive intervention | 2 | 2 | 2 |
| Withdrew: Other | 1 | 0 | 4 |
| Withdrew: Non-compliance | 0 | 0 | 4 |
Percentage of responders, defined as participants who met the following conditions: * Menstrual blood loss (MBL) volume \< 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period \[last treatment visit date\] or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and * ≥ 50% reduction in MBL volume from Baseline to the Final Month. Participants who prematurely discontinued study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or "adverse events" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.
| percentage of participants | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Percentage of Participants Meeting the Criteria for Responder | 8.7 | 84.1 | 68.5 |
Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.
| mL | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Change From Baseline in MBL Volume to the Final Month | 0.8 ± 14.86 | -221.5 ± 14.49 | -176.7 ± 10.40 |
Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.
| percentage of participants | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Percentage of Participants With Suppression of Bleeding at the Final Month | 4.4 | 84.0 | 56.8 |
| mL | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Change From Baseline in MBL Volume to Month 6 | -2.3 ± 13.53 | -236.2 ± 13.74 | -194.7 ± 9.77 |
| mL | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Change From Baseline in MBL Volume to Month 3 | 6.1 ± 15.32 | -234.7 ± 15.38 | -192.2 ± 10.81 |
| percentage of participants | Placebo | Elagolix | Elagolix + E2/NETA |
|---|---|---|---|
| Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6 | 16.1 | 65.9 | 61.5 |
| mL | Placebo | Elagolix | Elagolix + Estradiol/Norethindrone Acetate |
|---|---|---|---|
| Change From Baseline in MBL Volume to Month 1 | -19.0 ± 16.05 | -209.0 ± 15.91 | -135.2 ± 11.41 |
Collected over From first dose of study drug through 6 months of treatment with a 30-day follow-up period for participants who did not enroll in the extension study (Study M12-816). Mean (SD) treatment exposure was 158.6 (50.10), 161.2 (51.45), and 159.9 (53.48) days for the Placebo, Elagolix, and Elagolix and E2-NETA arms, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/102 (0%) | 5/102 (4.9%) | 29/102 (28.4%) |
| Elagolix | 0/104 (0%) | 3/104 (2.9%) | 81/104 (77.9%) |
| Elagolix + E2-NETA | 0/206 (0%) | 3/206 (1.5%) | 96/206 (46.6%) |
| Event | Placebo | Elagolix | Elagolix + E2-NETA |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 2/102 | 0/104 | 0/206 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 2/104 | 0/206 |
| OXYGEN SATURATION DECREASEDInvestigations | 1/102 | 0/104 | 0/206 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/102 | 0/104 | 0/206 |
| SUICIDAL IDEATIONPsychiatric disorders | 1/102 | 0/104 | 0/206 |
| MENORRHAGIAReproductive system and breast disorders | 1/102 | 1/104 | 0/206 |
| DYSPNOEA EXERTIONALRespiratory, thoracic and mediastinal disorders | 1/102 | 0/104 | 0/206 |
| PROLAPSEGeneral disorders | 0/102 | 1/104 | 0/206 |
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 0/102 | 1/104 | 0/206 |
| ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions | 0/102 | 1/104 | 0/206 |
| Event | Placebo | Elagolix | Elagolix + E2-NETA |
|---|---|---|---|
| HOT FLUSHVascular disorders | 9/102 | 67/104 | 42/206 |
| NIGHT SWEATSSkin and subcutaneous tissue disorders | 3/102 | 28/104 | 14/206 |
| HEADACHENervous system disorders | 9/102 | 17/104 | 17/206 |
| NAUSEAGastrointestinal disorders | 10/102 | 7/104 | 23/206 |
| FATIGUEGeneral disorders | 2/102 | 1/104 | 14/206 |
| INSOMNIAPsychiatric disorders | 6/102 | 7/104 | 5/206 |
| MOOD SWINGSPsychiatric disorders | 2/102 | 7/104 | 8/206 |
| DYSMENORRHOEAReproductive system and breast disorders | 4/102 | 1/104 | 13/206 |
| METRORRHAGIAReproductive system and breast disorders | 0/102 | 1/104 | 13/206 |
| NASOPHARYNGITISInfections and infestations | 4/102 | 6/104 | 10/206 |
All randomized and treated participants.
| Age, Continuous(years) | Placebo | Elagolix | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| Mean | 41.6 ± 5.68 | 42.6 ± 5.16 | 42.6 ± 5.30 | 42.3 ± 5.37 |
| Sex: Female, Male(Participants) | Placebo | Elagolix | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| Female | 102 | 104 | 206 | 412 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Elagolix | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| Hispanic or Latino | 19 | 4 | 34 | 57 |
| Not Hispanic or Latino | 83 | 100 | 172 | 355 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Elagolix | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 |
| Asian | 1 | 2 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 70 | 69 | 141 | 280 |
| White | 30 | 27 | 59 | 116 |
| More than one race | 1 | 4 | 1 | 6 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Dec 2015 to primary completion in Jan 2018, 24 months.
Results were first posted in Jun 2020, 2 years 5 months after primary completion. A results delay was requested in Dec 2018.
Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elagolix · Estradiol · Norethindrone Acetate